Development of a vaccine against invasive pneumococcal disease based on combinations of virulence proteins of Streptococcus pneumoniae.
about
The role of zinc in the interplay between pathogenic streptococci and their hostsStructure of a complex of human lactoferrin N-lobe with pneumococcal surface protein a provides insight into microbial defense mechanismA Molecular Mechanism for Bacterial Susceptibility to ZincStructural determinants of host specificity of complement Factor H recruitment by Streptococcus pneumoniaeDiscovery of a novel class of highly conserved vaccine antigens using genomic scale antigenic fingerprinting of pneumococcus with human antibodiesDiversity of pneumococcal surface protein A (PspA) among prevalent clones in SpainThe Pneumococcal Alpha-Glycerophosphate Oxidase Enhances Nasopharyngeal Colonization through Binding to Host Glycoconjugates.Immunization with a combination of three pneumococcal proteins confers additive and broad protection against Streptococcus pneumoniae Infections in MicePotential role for mucosally active vaccines against pneumococcal pneumoniaA longitudinal study of natural antibody development to pneumococcal surface protein A families 1 and 2 in Papua New Guinean Highland children: a cohort studyInteraction of pneumococcal histidine triad proteins with human complement.Mapping of epitopes recognized by antibodies induced by immunization of mice with PspA and PspC.Contributions to protection from Streptococcus pneumoniae infection using the monovalent recombinant protein vaccine candidates PcpA, PhtD, and PlyD1 in an infant murine model during challengeBiofilm and planktonic pneumococci demonstrate disparate immunoreactivity to human convalescent seraPreclinical evaluation of the Pht proteins as potential cross-protective pneumococcal vaccine antigens.Immunization with a ZmpB-based protein vaccine could protect against pneumococcal diseases in mice.Lactococcus lactis as an adjuvant and delivery vehicle of antigens against pneumococcal respiratory infectionsCharacterization of protective immune responses induced by pneumococcal surface protein A in fusion with pneumolysin derivatives.NADH oxidase functions as an adhesin in Streptococcus pneumoniae and elicits a protective immune response in mice.Natural antibodies against several pneumococcal virulence proteins in children during the pre-pneumococcal-vaccine era: the generation R study.Designed reduction of Streptococcus pneumoniae pathogenicity via synthetic changes in virulence factor codon-pair biasVaccination against Streptococcus pneumoniae using truncated derivatives of polyhistidine triad protein DConserved surface accessible nucleoside ABC transporter component SP0845 is essential for pneumococcal virulence and confers protection in vivo.Two DHH subfamily 1 proteins contribute to pneumococcal virulence and confer protection against pneumococcal disease.In vitro biofilm development of Streptococcus pneumoniae and formation of choline-binding protein-DNA complexes.Delayed reconstitution of B cell immunity to pneumococcus in HIV-infected Malawian children on antiretroviral therapy.Novel protein-based pneumococcal vaccines administered with the Th1-promoting adjuvant IC31 induce protective immunity against pneumococcal disease in neonatal mice.RrgB321, a fusion protein of the three variants of the pneumococcal pilus backbone RrgB, is protective in vivo and elicits opsonic antibodies.Building the microbiome in health and disease: niche construction and social conflict in bacteria.Live attenuated Streptococcus pneumoniae strains induce serotype-independent mucosal and systemic protection in mice.Active Immunization with Pneumolysin versus 23-Valent Polysaccharide Vaccine for Streptococcus pneumoniae KeratitisCharacterization of Pneumococcal Genes Involved in Bloodstream Invasion in a Mouse ModelCross-reactivity of antipneumococcal surface protein C (PspC) antibodies with different strains and evaluation of inhibition of human complement factor H and secretory IgA binding via PspC.Identification of a novel pneumococcal vaccine antigen preferentially expressed during meningitis in mice.PspA family distribution, unlike capsular serotype, remains unaltered following introduction of the heptavalent pneumococcal conjugate vaccine.Neutralizing antibodies elicited by a novel detoxified pneumolysin derivative, PlyD1, provide protection against both pneumococcal infection and lung injuryNasopharyngeal colonization elicits antibody responses to staphylococcal and pneumococcal proteins that are not associated with a reduced risk of subsequent carriage.Multivalent Pneumococcal Protein Vaccines Comprising Pneumolysoid with Epitopes/Fragments of CbpA and/or PspA Elicit Strong and Broad Protection.Identification of genes that contribute to the pathogenesis of invasive pneumococcal disease by in vivo transcriptomic analysis.Controlled inflammatory responses in the lungs are associated with protection elicited by a pneumococcal surface protein A-based vaccine against a lethal respiratory challenge with Streptococcus pneumoniae in mice.
P2860
Q27003448-E7DC1FBD-A285-4E95-88EC-964654572CA0Q27645143-F35FB9B4-F2D9-4817-AAA9-F46FF98E8FA5Q27675498-AB1055C5-1398-4FED-8710-9D371F1ECF5BQ27695722-134C3B5D-C20F-43DB-8E3A-50896C7AAB3EQ33312893-8EDB1E4F-00C4-49B0-96C1-3BE3761B23DFQ33439975-27F9791D-FE98-4B58-8B3F-5719A636626AQ33603644-B941A3B7-85B2-4E60-B7D2-87477B58E23CQ33675920-90F87357-C227-41CB-A28D-F9758026CC88Q33792681-ABF943DB-9002-43B3-86A7-9CAEA4B6FE92Q33802029-5B15C1AC-06D8-47F0-9C1A-3900AE14FA5EQ33826119-B283BE42-DED1-4222-B1D1-8BB92541A744Q33899358-605971AD-FCE1-496A-AA84-6F0D2FCD9616Q34057765-FC6C6D2A-D0FE-4958-810A-5AA8E9D1FD73Q34065036-6204C008-C1FB-4A31-8B24-541E1710E37DQ34484575-098F012D-D511-4382-B6EA-81EFF025F3CCQ34529480-13DDC3CD-F795-4464-8275-6B1F76CE6739Q34568182-1C08403E-951B-483B-BD40-52C6CB0888CCQ34637890-42CAD1C0-26B8-4D27-9A02-B117BD90D780Q34664119-EC93AEC8-FC5D-4E22-8B3D-3973CA2A2280Q34740228-A4B780DE-FD0A-4D08-8CC5-73614B335236Q34754860-41EE190D-2667-42E8-AE87-F964C4829A60Q35036855-244ADC61-75EF-4156-BA2B-FC6ADA912825Q35092077-E3138952-FC5A-4651-BB2A-CACAA88CCE26Q35191928-9DA05D48-1BED-4B56-A8AF-A8E0FE9DD295Q35624139-1452CD7A-680F-4C0B-9BAB-1474DDA0C193Q35635685-8C2D4F65-153C-4674-94F1-54FED5B10678Q35665351-DA86A71C-DE3D-4CDB-86EF-EAF25A7A5E83Q35665417-31E50551-16D7-4327-BEAC-8002AD29CFDEQ35684956-D04E9BDC-089D-497E-86BC-0AB57DD4534BQ35784046-CCC23738-0212-4E8A-AD78-39F3C9081320Q35826641-520CC377-2E14-4CD1-BD57-585A15A40E97Q35833224-DFA831C7-1DA6-4928-AAF3-ACDB4FF90BD3Q35867202-9BE56462-60FA-43F5-97EC-BA77BE00F9BEQ36005317-CCA45221-15EC-47EA-BAFF-E3C6264D12E0Q36017785-7D4AFD9D-1CAE-42C8-9114-7F5F5A48B736Q36018158-3BD3186A-3658-47A0-ABCE-4B5BA7F98A20Q36018177-6D042078-1F85-4B13-B477-515F6A329B40Q36087567-B9A10BDD-C1B6-4D6D-B795-8395F6CE0256Q36163091-2C44675D-6476-4D44-9F6A-6527AC96DD51Q36191618-8BE7084B-4A69-4BB6-94F5-F31E95101A52
P2860
Development of a vaccine against invasive pneumococcal disease based on combinations of virulence proteins of Streptococcus pneumoniae.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Development of a vaccine again ...... s of Streptococcus pneumoniae.
@ast
Development of a vaccine again ...... s of Streptococcus pneumoniae.
@en
type
label
Development of a vaccine again ...... s of Streptococcus pneumoniae.
@ast
Development of a vaccine again ...... s of Streptococcus pneumoniae.
@en
prefLabel
Development of a vaccine again ...... s of Streptococcus pneumoniae.
@ast
Development of a vaccine again ...... s of Streptococcus pneumoniae.
@en
P2093
P2860
P356
P1476
Development of a vaccine again ...... ns of Streptococcus pneumoniae
@en
P2093
Abiodun D Ogunniyi
David E Briles
James C Paton
P2860
P304
P356
10.1128/IAI.01103-06
P407
P577
2006-11-06T00:00:00Z